» Articles » PMID: 27368058

Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis

Overview
Journal PLoS One
Date 2016 Jul 2
PMID 27368058
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

An unprecedented advance has been seen in castration-resistant prostate cancer (CRPC) treatments in the past few years. With a number of novel agents were approved, there is a pressing need to develop improved prognostic biomarkers to facilitate the personalised selection and sequencing of these novel agents. Emerging evidence indicates that the neutrophil-to-lymphocyte ratio (NLR) is associated with poorer survival in patients with prostate cancer (PCa). However, the importance of the NLR for the prediction of the PSA response (PSARS) and biochemical recurrence (BCR) has been largely neglected. Here, we conducted a systematic review and meta-analysis to evaluate the prognostic value of the NLR for the PSARS, BCR, and survival in PCa. A systematic database search was performed using Embase, PubMed, the Cochrane Library, and the China National Knowledge Infrastructure (CNKI). A meta-analysis was performed by pooling hazard ratios (HRs), odds ratios (ORs) and the corresponding 95% confidence intervals (CIs). A total of 22 studies were included in the meta-analysis. Our results suggest that an elevated NLR predicts a lower PSARS rate (OR = 1.69, 95% CI: 1.40-1.98) and a higher possibility of BCR (HR = 1.12, 95% CI: 1.02-1.21). Additionally, we confirmed that an elevated NLR was a prognostic predictor of shorter overall survival (OS) in both metastatic castration-resistant PCa (mCRPC) (HR = 1.45, 95% CI: 1.32-1.59) and localized PCa (LPC) (HR = 1.12, 95% CI: 1.01-1.23) and that it predicted worse progression-free survival (PFS) in CRPC (HR = 1.42, 95% CI: 1.23-1.61) and poorer recurrence-free survival (RFS) (HR = 1.38, 95%CI: 1.01-1.75) in LPC. Our results suggest that an elevated NLR might be employed as a prognostic marker of biochemical changes and prognosis to facilitate risk stratification and decision making for individual treatment of PCa patients. The potential mechanisms underlying these associations and future research directions are also discussed.

Citing Articles

Inflammation-related indicators have a potential to increase overall quality of the prostate cancer management: a narrative review.

Zhou M, Liang J, Hui J, Xu J Transl Androl Urol. 2023; 12(5):809-822.

PMID: 37305618 PMC: 10251092. DOI: 10.21037/tau-23-55.


Endocrine and paracrine characteristics of neuroendocrine prostate cancer.

Arman T, Nelson P Front Endocrinol (Lausanne). 2022; 13:1012005.

PMID: 36440195 PMC: 9691667. DOI: 10.3389/fendo.2022.1012005.


Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer.

Meisel A, de Wit R, Oudard S, Sartor O, Stenner-Liewen F, Shun Z Ther Adv Med Oncol. 2022; 14:17588359221100022.

PMID: 35677318 PMC: 9168856. DOI: 10.1177/17588359221100022.


Influence of Semiquantitative [F]FDG PET and Hematological Parameters on Survival in HNSCC Patients Using Neural Network Analysis.

Cegla P, Currie G, Wroblewska J, Cholewinski W, Kazmierska J, Marszalek A Pharmaceuticals (Basel). 2022; 15(2).

PMID: 35215335 PMC: 8875232. DOI: 10.3390/ph15020224.


Correlation between neutrophil-to-lymphocyte ratio with Gleason score in patients with prostate cancer at Adam Malik Hospital Medan 2013 - 2015.

Rulando M, Putra Siregar G, Mirsya Warli S Urol Ann. 2021; 13(1):53-55.

PMID: 33897165 PMC: 8052910. DOI: 10.4103/UA.UA_1_20.


References
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

2.
Kim J, Bae J . Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm. 2016; 2016:6058147. PMC: 4757693. DOI: 10.1155/2016/6058147. View

3.
Muranski P, Restifo N . Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol. 2009; 21(2):200-8. PMC: 2715842. DOI: 10.1016/j.coi.2009.02.004. View

4.
Diaz-Montero C, Salem M, Nishimura M, Garrett-Mayer E, Cole D, Montero A . Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2008; 58(1):49-59. PMC: 3401888. DOI: 10.1007/s00262-008-0523-4. View

5.
Wei Y, Jiang Y, Qian W . Prognostic role of NLR in urinary cancers: a meta-analysis. PLoS One. 2014; 9(3):e92079. PMC: 3958449. DOI: 10.1371/journal.pone.0092079. View